EN DE
Watch Clicks for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Clicks (CLS) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of Clicks stock R236.96, price R200.39, upside +18.2%, quality 71 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare ZA · ISIN ZAE000134854

C Clicks logo Broad data Nov 21, 2026

Clicks

CLS · JSE

Solid company, but only slightly cheap (15% below fair value) and falling price: meets 1 of 3 rules.

Follow free in the weekly email
Fair value R236.96 · Undervalued 
Quality 71/100 
Healthy Growth (revenue 5y +7.8 %/yr in ZAR) 
Generates free cash flow 
Ranks above peers (8/13) 
Recent news very positive 
Broad data 
49% return on equity. 
Thin margins · 6.6% net margin (TTM) 
Moderate moat 55/100
Falling price (downtrend) 
Watch Clicks for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

R385.54 R186.13 Fair Value R236.96 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 21, 2026.

How to read this chart

60‑month range R186.13 – R385.54 · fair‑value band R165.26 – R329.85 · the R200.39 price screens below the R236.96 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 21, 2026.

Follow Clicks in your weekly email

Every Wednesday you see whether Clicks is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Clicks Group Limited, together with its subsidiaries, operates as a health, wellness, and beauty retailer in South Africa and internationally. The company operates through two segments, Retail and Distribution.

Show moreShow less

It provides retail, including Clicks, a specialist health, beauty and homeware retailer; Sorbet, a franchise of hair and beauty salons; 180 Degrees Marketing, a software development company; and The Body shop, which specializes in naturally inspired luxury toiletries, cosmetics, gifting and grooming, with stores.

The company also offers various ranges of mother-and-baby products, including baby hardware, accessories, health, food, diaper and wipes, and baby toiletries under the Clicks Baby brand; and diabetic clinic, travel clinic, and wound management practice under the M-KEM brand.

In addition, the company is involved in the wholesale and supply of pharmaceutical products to retail pharmacies, private hospitals, dispensing doctors, and retail health stores under the UPD brand.

The company was formerly known as New Clicks Holdings Limited and changed its name to Clicks Group Limited in June 2009. Clicks Group Limited was founded in 1968 and is headquartered in Cape Town, South Africa.

Stock analysis

Clicks (CLS) currently trades at R200.39, while our model-based Fair Value estimate is R236.96, implying the stock looks roughly 15% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of R284.71 per share, and 17 of the 26 models we run sit above the R200.39 price.

Bear case: the Economic Profit group reads lowest at R119.36, and 9 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: R165.26 (bear) to R329.85 (bull), the price of R200.39 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Clicks reported revenue of 54.3B ZAR in FY2026 versus 39.6B ZAR in FY2022, a compound +8.2%/yr. Reported net income was 3.3B ZAR in FY2026, compounding +5.9%/yr from FY2022.

Key figures

Market cap 46.8B ZAR Mid · P/E ratio 13.6 · P/S ratio 0.93 · EPS (TTM) R14.77 · Dividend yield 4.6% · Net margin 6.6% · Return on equity 48.6% · Return on assets (EBIT) 20.1% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (medium confidence).

What moves the price

The share trades about 42% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 18% fair-value upside, at 18%, CLS screens cheaper than that median.

Fair Value models

Bear R165.26 Fair Value R236.96 Bull R329.85
Price R200.39 · Upside +18.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 3 months old). Earnings retained since then (R1.26 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF R166.31 R245.41 R353.64 78
Growth DCF R165.26 R236.96 R329.85 76
Owner Earnings R163.02 R240.46 R346.41 74
All 26 models by family
DCF Models
FCF DCF R166.31 R245.41 R353.64 78
Owner Earnings R163.02 R240.46 R346.41 74
5Y Revenue Exit R181.65 R294.39 R442.06 69
5Y EBITDA Exit R226.92 R382.98 R571.50 71
5Y P/E Exit R191.86 R314.36 R447.79 68
10Y Revenue Exit R168.06 R262.55 R396.63 64
10Y EBITDA Exit R198.63 R317.89 R487.07 65
10Y P/E Exit R178.63 R275.03 R400.63 61
Earnings-Based
Graham-Dodd R96.50 R370.49 R502.03 64
Lynch FV R136.51 R195.02 R253.53 61
PEG = 1.0 R136.51 R195.02 R253.53 57
EPV R127.74 R142.61 R154.79 70
Dividend Discount
Gordon GGM R98.54 R169.51 R224.60 68
DDM Multi-Stage R98.54 R158.63 R181.92 67
Multiples
P/E Multiple R223.51 R298.02 R372.52 63
P/S Multiple R180.94 R241.25 R301.56 58
P/B Multiple R97.00 R129.34 R161.67 55
EV/EBIT R257.70 R346.71 R435.73 63
EV/EBITDA R280.46 R377.07 R473.68 64
EV/Revenue R181.25 R262.93 R344.62 51
Asset-Based
NCAV (Graham) R11.76 R15.76 R23.52 51
Growth DCF
Growth DCF R165.26 R236.96 R329.85 76
Rev-Margin DCF R181.65 R293.19 R428.99 69
Economic Profit
Residual Income R64.91 R85.19 R152.34 73
ROIC Compounder R132.67 R153.53 R173.99 70
Growth Earnings
Growth-Adj P/E R163.72 R233.88 R304.05 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 71/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 83
How much profit the company makes from its sales and capital
Quality Growth 43
Are margins and returns getting better?
Cashflow 52
Do the profits arrive as real cash?
Financial strength 71
Debt, balance sheet and risk of trouble
Investment 79
Does it invest with discipline instead of growing at any price?
Low Volatility 81
How calm the share price moves, does not count
Price momentum 22
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 5
Distance to the 52-week high, does not count
New shares 97
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 76/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.8%
Start year 2021 (pandemic). Over 10 years: +8.4% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.0%
What shareholders gained per year (last 5 years), in ZAR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in ZAR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+18.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+13.6%
Dividend (yield on the price)4.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.13.6% vs 12.5%, steady
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 9%
Pace: the 5-year rate starts in 2021 (pandemic)

Growth Forecast

Price in line with expectations
The price assumes about as much growth as the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (South Africa: IMF forecast 3.3% a year to 2030, 4.9% from 2016 to 2025) that is about +2.0% a year for the price and +1.1% for the forecasts.
Forecast 2027 (sales)−1.4%
Forecast 2028 (sales)+6.8%
Projected 2029 (sales)+6.2%
Projected 2030 (sales)+5.6%
Projected 2031 (sales)+5.0%

Watch CLS, get fair value alerts →

Earlier news

News mood ⓘNews mood, the average tone of recent news (11 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.

Compare Clicks with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 55 stocks

Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 71 · Top 25%
Fair Value upside +18.2% · Below median
Profitability
Return on equity (12 months) 48.6% · Top 25%
Return on assets 13.8% · Top 25%
Net margin (12 months) 6.6% · Top 25%
Operating margin (12 months) 9.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 3.6% · Below median
Dividend yield (12 months) 4.6% · Above median

Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper

P/E (12 months) 13.6× · Cheapest 25%
P/B 6.88× · Priciest 25%
P/S (12 months) 0.93× · Pricier than median
Price / free cash flow (fiscal year) 12.9× · Pricier than median
EV/EBITDA 6.4× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)58 · sector 61
FUTURE (revenue growth)18 · sector 24
PAST (return on equity)100 · sector 24
HEALTH (low debt)–
DIVIDEND (yield)92 · sector 53

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate.

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Clicks: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Clicks Fair Value". https://www.fairvalue-calculator.com/stock/CLS.JSE

Frequently asked questions

Is Clicks (CLS) overvalued or undervalued?
As of Nov 21, 2026, our model estimates a fair value of R236.96 versus a price of R200.39, about +18% upside (undervalued).
What is the fair value of CLS?
Our model-based fair value for Clicks is R236.96 (as of Nov 21, 2026), built from audited fundamentals. The current price: R200.39.
What is the quality score of CLS?
Clicks has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Clicks (CLS)?
We do not set a price target; the yardstick is the fair value of R236.96 (as of Nov 21, 2026) from 26 valuation models. Cautious scenario R165.26, optimistic scenario R329.85. It is a calculation from audited fundamentals, not an analyst target.
What is the Clicks stock forecast for 2026?
Our models put fair value at R236.96, about +18% upside versus a price of R200.39 (undervalued). Cautious scenario R165.26, optimistic scenario R329.85. The calculation is refreshed regularly with new filings.
What is the revenue of Clicks (CLS)?
Clicks reported trailing-twelve-month revenue of about 50.4B ZAR (latest available figure, as of Nov 21, 2026).
Does Clicks pay a dividend?
Clicks currently shows a dividend yield of 4.62% relative to its recent price (as of Nov 21, 2026).
How much is the dividend of Clicks (CLS) and when is the ex-dividend date?
Clicks pays a dividend of R9.25 per share a year, a dividend yield of 4.6%. The next ex-dividend date is Jan 20, 2027. A dividend has been paid every year since at least 1996. The payout ratio is 62.6% of earnings. Free cash flow covers the dividend 1.68 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Clicks (CLS)?
For today's price to be fair in a discounted-cash-flow model, Clicks would have to grow free cash flow by 5.3 % per year for five years (discount rate 11.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 7.8 % per year. As of Nov 21, 2026.
What discount rate (WACC) does the fair value of CLS use?
Our models discount Clicks at 11.9 %: a base by market capitalisation (mid), damped by beta 0.08, country premium for South Africa. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Clicks that is +5.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.9 %) and the same formula as our fair value.
How much growth has Clicks (CLS) delivered so far?
Over the past 5 years revenue at Clicks grew 7.8 % a year. The price currently implies free-cash-flow growth of +5.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Clicks (CLS) growing?
The median revenue growth in the sector is +4.0 % a year. That is the yardstick for the growth priced into Clicks (+5.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Clicks (CLS)?
The free-cash-flow yield on the price is 7.77 %: that much free cash flow Clicks produces per unit of market value. When it exceeds the discount rate of our models (11.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Clicks (CLS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Clicks it is R236.96 per share (as of Nov 21, 2026), against a price of R200.39. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Clicks stock overvalued or undervalued in 2026?
As of Nov 21, 2026, CLS trades below its calculated fair value: price R200.39, fair value R236.96, a gap of about +18% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CLS?
No. The price is what the market pays today (R200.39); the fair value is what the company's own numbers justify (R236.96). For Clicks the two are R36.57 per share apart. That gap is exactly why we show both numbers side by side.
How much is Clicks worth?
The market values Clicks at about 46.8B ZAR (market capitalisation, as of Nov 21, 2026). Per share that is R200.39; our models calculate a fair value of R236.96 per share.
What do the bullish and bearish scenarios say about CLS?
Our models span a range for Clicks: cautious scenario R165.26, base R236.96, optimistic R329.85 per share (as of Nov 21, 2026, price R200.39). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CLS?
Clicks trades at a price-to-earnings ratio of 13.6 (as of Nov 21, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of R236.96 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings: 29.5. Other multiples: PEG 141.4, P/B 6.9, P/S 0.9, EV/EBITDA 6.4.
What is the PEG ratio of CLS?
The PEG ratio of Clicks is 141.41 (P/E divided by earnings growth, as of Nov 21, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Clicks (CLS)?
Balance-sheet figures for Clicks (as of Nov 21, 2026): return on equity 48.6%. They feed the Quality Score of 71/100, which measures business quality independently of the share price.
How far is CLS from its 52-week high?
Clicks trades at R200.39, about 42% below its 52-week high of R343.95 and 8% above the low of R186.13 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of R236.96 is for.
Which stocks are comparable to Clicks?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Clicks stock attractive at the current price?
The data as of Nov 21, 2026: price R200.39, calculated fair value R236.96 (+18%), Quality Score 71/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CLS calculated?
We run Clicks through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of R236.96 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 10.1% above its aggregate fair value. Clicks currently trades 15% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Clicks (CLS)?
The closing price on Nov 20, 2026 was R200.39. Our model-based fair value is R236.96, about +18% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Clicks right now?
A fairly wide model range (R165.26 to R329.85) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Clicks (CLS) come from?
Earnings per share at Clicks grew 13.0 % a year from 2015 to 2026. Broken into its drivers: revenue per share +9.1 %, EBIT margin +3.7 %, tax rate +0.2 %, residual (interest, one-offs) −0.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Clicks

How large is the market capitalisation of Clicks (CLS)?
The market capitalisation of Clicks is 46.8B ZAR. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Clicks (CLS)?
The price-to-sales ratio of Clicks is 0.93 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Clicks (CLS)?
Earnings per share at Clicks are R14.77 (price ÷ EPS = P/E 13.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Clicks (CLS)?
The dividend yield of Clicks is 4.6% (payout 62.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Clicks (CLS)?
The net margin of Clicks is 6.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Clicks (CLS)?
The return on equity (ROE) of Clicks is 48.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Clicks (CLS)?
On an EBIT basis the return on assets of Clicks is 20.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Clicks (CLS)?
The operating margin of Clicks is 9.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Clicks (CLS)?
Revenue at Clicks is growing 3.6% in the last quarter versus the same quarter a year earlier (3y avg +9.3%). How much revenue grew in the last quarter versus the same quarter a year earlier (YoY). The 3-year average next to it puts the single quarter in context.
How fast are earnings growing at Clicks (CLS)?
Earnings per share at Clicks are growing 0.9% in the last quarter versus the same quarter a year earlier. How much earnings per share grew in the last quarter versus the same quarter a year earlier.
How much net debt does Clicks (CLS) carry?
The net debt of Clicks is 2.2B ZAR (fiscal year 2026, ≈ 0.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Clicks in the live analysis

One click puts Clicks on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.